Text or WhatsApp Richard at (808) 600-9260
Lion crestHealthcareInvestmentBanking.com
Family Office Club credibility badge

Healthcare M&A, valuation and capital raising

Healthcare Investment Banking: M&A, Valuation and Capital Raising

Checklists, calculators and guides for healthcare owners raising capital, selling or recapitalizing, and the family offices that back them.

Start with the checklists Run the calculators

Healthcare Investment Banking: M&A, Valuation and Capital Raising

Healthcare investment banking is advisory work on selling, buying and raising capital for healthcare companies. For an owner, the work comes down to three numbers: the multiple a buyer will pay, how much of your EBITDA survives diligence, and how much of the headline price arrives as cash at closing. Buyers are active. Of the 1,029 private equity-backed healthcare deals the Private Equity Stakeholder Project (PESP) tracked in calendar 2025, 664 were add-ons by platforms that already own practices. Most owners will sell to one of those platforms or to a health system, or raise minority capital from family offices or physicians. This page shows how each path works, what the 2026 data says about pricing, and how to compare offers on cash instead of headline.

The spending base behind these deals keeps growing. Per the CMS National Health Expenditure fact sheet, US health spending grew 7.2% to $5.3 trillion in 2024, or 18.0% of GDP. Physician and clinical services spending grew 8.1% to $1,109.7 billion, and CMS projects it will grow 5.5% a year on average from 2025 to 2034.

This page covers US provider services and healthtech: physician and dental practices, outpatient platforms, behavioral health, health IT, medtech and hospitals. Biopharma IPOs and follow-on offerings run on their own public-market cycle and are not covered here.

Data as of November 20, 2026. Each figure names its source, population and period. Worked examples are labeled as our arithmetic and state their assumptions.

Seven Checks Before You Sign a Letter of Intent

Check What the data says What to do
1. Who is my likeliest buyer? Add-ons were 664 of the 1,029 PE healthcare deals PESP tracked in 2025 Start your buyer list with platforms that already own practices in your specialty
2. Which multiple reference applies? Listed US EV/EBITDA runs from 8.86x (hospitals/facilities) to 21.27x (health IT) in Damodaran's January 2026 data Ask each bidder which private comparables its price relies on and how old they are
3. Will my EBITDA survive diligence? Buyers rebuild EBITDA at market owner pay and fair market rent Commission your own quality of earnings review before you go to market
4. How much of the headline is cash at closing? 58% to 73% of headline, before fees and taxes, in the illustrative offers below. That range comes from assumed escrow, debt and consideration mix, so it is not a market benchmark Compare offers on closing cash, not headline price
5. Is there an earnout? Earnout dollars depend on post-closing results Value each earnout dollar at your honest odds of collecting it
6. Can a regulatory filing delay closing? Federal and state reviews can set the earliest closing date. Practice ownership rules and physician referral rules can affect structure. Requirements vary by jurisdiction and deal Have your attorney map filings and timing before the LOI (see LOI terms to lock down below)
7. Is the adviser registered? Registration and disciplinary history are public Look up the banker and firm on FINRA BrokerCheck

Test any offer against our LOI and term sheet red flags checklist.

Who Buys: 1,029 PE Healthcare Deals in 2025 and 56 Hospital Deals Through Q3 2026

Metric Value Source Population and period
PE-backed healthcare deals 1,029: 664 add-ons, 214 growth investments, 151 leveraged buyouts PESP PE-backed deals, all healthcare subsectors, calendar 2025
Participants 420 platform companies, 708 investment firms PESP Same population, calendar 2025
Busiest subsectors Health IT 151, dental 149, outpatient 148, medtech 117, behavioral health 56 PESP Same population, calendar 2025
Top outpatient specialties Dermatology 24, eye care 22, oncology 9 PESP data reported by Becker's ASC Review PE-backed outpatient deals, calendar 2025
Outpatient add-ons 119 of 148 outpatient deals PESP data reported by Becker's ASC Review PE-backed outpatient deals, calendar 2025
Hospital and health system deals 56 announced, compared with 46 in all of 2025 Kaufman Hall data reported by Becker's Hospital Review Hospital and health system deals, Jan 1 to Sep 30, 2026

PESP and Kaufman Hall count different things. PESP counts private equity-backed deals across every healthcare subsector. Kaufman Hall counts only hospital and health system transactions. Don't add the two counts together or compare them.

Add-ons dominate PE deal flow. By our arithmetic, add-ons made up about 65% of PESP's 2025 total (664 ÷ 1,029) and about 80% of outpatient deals (119 ÷ 148). Dental is the extreme case. PESP reports that 95% of its 149 dental deals in 2025 were add-ons by PE-owned platforms, and 10 of the 18 platforms with the most deals that year were dental companies. PESP built its count from PitchBook and LevinPro HC and says the total is likely an underestimate, so read these figures as a floor. For most practices, the likeliest PE buyer is a platform in the same specialty, not a fund making its first purchase. Our guide to private equity physician roll-ups explains the platform model.

The scale physician group model is mainly a US model. Bain & Company's Global Healthcare Private Equity Report 2026 finds that investment in scale physician groups is far less common in Europe, where national markets are fragmented and regulation differs by country.

Hospitals run on their own cycle. Kaufman Hall's data shows a sector under margin pressure that is consolidating at the top.

Kaufman Hall hospital and health system data Figure Period Source
Deals announced, Q1 / Q2 / Q3 22 / 18 / 16 2026 Becker's Hospital Review
Full-year count, prior year 46, the lowest since tracking began in 2011 Calendar 2025 Becker's Hospital Review
Q3 compared with a year earlier Matched prior-year activity Q3 2026 vs Q3 2025 Kaufman Hall
Transacted revenue $8.2 billion Q3 2026 Kaufman Hall
Average seller size Approaching $586 million of annual revenue Q3 2026 Kaufman Hall
Mega mergers announced 2, the third straight quarter with mega mergers Q3 2026 Kaufman Hall
Divestitures Nearly one-third of announced deals Q3 2026 Kaufman Hall
Most common acquirer Not-for-profit organizations Q3 2026 Kaufman Hall
Operating margin, including allocations 2.5% Year to date through August 2026 Kaufman Hall
Hospitals operating at a loss Nearly 43% Through August 2026 Kaufman Hall
Non-labor expense per adjusted discharge Up 6% vs 2025 (supplies up 5%, drugs up 6%) Year to date through August 2026 Kaufman Hall

Kaufman Hall defines a mega merger as a deal in which the smaller party has more than $1 billion of annual revenue, and it says 2026 could become a record year for them. The 56 deals through Q3 2026 already exceed 2025's full-year 46, yet quarterly counts fell from 22 to 18 to 16. The two Q3 size figures don't reconcile by division. $8.2 billion over 16 deals is about $513 million per deal (our arithmetic), while Kaufman Hall reports average seller size approaching $586 million. Cite each figure as reported.

The margin data explains the divestitures. With nearly 43% of hospitals operating at a loss through August 2026, systems are selling non-core assets. If you co-own an ASC, imaging center or physician group with a hospital partner, that system may come to the table to sell its stake as often as to buy yours.

Six Ways to Take Capital Off the Table

Owners rarely face a simple choice between selling and not selling. The real choice is between structures that trade cash today against control and future upside.

Path What you give up What you get Best fit Deal count, PESP 2025
Add-on sale to a PE platform Control, usually all or most of the equity Cash at closing plus rollover in the platform Practices in specialties with active platforms 664 add-ons
Platform sale (majority recap) Majority control A large cash payout, meaningful rollover and a board seat Groups large enough to anchor a new platform 151 leveraged buyouts
Minority growth investment A minority stake and some veto rights Growth capital while you keep control Profitable companies with a clear use of funds 214 growth investments
Hospital or health system affiliation Independence, and often equity Employment, capital and stronger payer contracting Practices tied to one system's referral base Outside PESP's count
Family office or physician investor round A minority stake Patient capital without a sponsor's exit deadline Founders who want long hold periods Outside PESP's count
Internal sale to an associate Full ownership, over a transition period Continuity for patients and staff Smaller practices with a successor in place Outside PESP's count

An internal sale is usually financed with bank debt. The SBA 7(a) program, the SBA's main small business loan program, sets a maximum loan amount that can change, so confirm the current limit with your lender. Lender credit standards and loan structure can lower the practical limit further, which constrains how large a practice an associate can buy without outside equity.

If your situation is... The path that usually fits
Under $2M EBITDA, a single specialty, and platforms active in your region Add-on sale, run competitively across several platforms
Over $10M revenue with a management team that runs without you Platform sale, or a minority growth round if you want to keep control
A clear growth plan, profitable operations and no wish to sell Minority growth equity or a family office round
Most referrals flowing through one health system A health system affiliation, tested against at least one PE bid
Near retirement with a trusted associate Internal sale, priced against at least one outside bid
Near retirement with no successor Add-on sale with a short employment term and little rollover

What a Healthcare Investment Banker Does

Mandate Client Core work
Sell-side advisory An owner selling or recapitalizing Prepares the company, builds the buyer list, runs a competitive process and negotiates the purchase agreement
Buy-side advisory A platform, health system or investor Finds and screens targets, then prices and structures the acquisition
Capital raising A founder or sponsor Places equity or debt to fund growth, acquisitions or partial liquidity

Pay usually combines a monthly or upfront retainer with a success fee paid at closing. Ask any adviser four questions before you sign an engagement letter:

Worked example: what the fee base costs you. Assume a 2% success fee on the $45 million deal modeled below (illustrative inputs, our arithmetic).

Fee base component Amount Fee at 2% When the seller receives that value
Cash consideration $33.75M $675,000 At closing, less escrow and debt payoff
Rollover equity $6.75M $135,000 At the platform's next sale, if it goes well
Earnout $4.50M $90,000 Only if post-closing targets are hit
Headline enterprise value $45.00M $900,000

If the letter sets the fee on headline enterprise value and makes all of it payable at closing, the seller pays $225,000 on value not yet received in cash: $135,000 on rollover units and $90,000 on an earnout that may never pay. The full $900,000 equals about 3.4% of the $26.25 million net closing cash in this example. Negotiate the rollover portion as payable at its liquidity event and the earnout portion as payable when the earnout pays. Engagement letters define the fee base differently, and some include assumed debt or exclude rollover, so read the definition, not just the percentage.

Our guides to how healthcare bankers get paid and how to choose a healthcare investment banker cover fee structures and vetting.

How a Sell-Side Process Runs

Stage What happens What the seller should do
1. Preparation Seller-side quality of earnings, data room build, normalized EBITDA Fix owner pay, rent and coding issues before a buyer finds them
2. Marketing Teaser, NDA and confidential information memorandum sent to a targeted list Include every platform in your specialty and region, plus one or two strategic buyers
3. Indications of interest Non-binding price ranges and structure Require cash, rollover and earnout as separate numbers
4. Management meetings Buyers meet owners and operators Show who runs daily operations without the founder
5. Letter of intent Price, structure, exclusivity and key terms Settle escrow, the earnout metric and rollover rights while you still have competition
6. Confirmatory diligence Financial, billing, legal, regulatory and clinical review Answer from the data room, not from memory
7. Signing and closing Purchase agreement, regulatory filings, funds flow Reconcile the funds flow memo to the LOI line by line

Your negotiating power peaks before the LOI. Once you grant exclusivity, you negotiate every open term with a single buyer.

Valuation in 2026: Listed Hospitals at 8.86x and Health IT at 21.27x EBITDA

Listed US sector, Damodaran, NYU Stern, January 2026 Firms in sample EV/EBITDA
Healthcare Information and Technology 115 21.27x
Healthcare Products 204 19.78x
Healthcare Support Services 104 11.17x
Hospitals/Healthcare Facilities 31 8.86x

Use this table for its ranking. Technology and products trade well above services and facilities. These are public-company multiples that include the value of liquid shares, and the hospital figure rests on only 31 companies. A bid for a private practice is built from private transaction comparables in the buyer's and banker's deal databases. Ask every bidder to name the private deals behind its multiple, with dates.

Size moves the multiple most. FOCUS Investment Banking's 2026 dashboard reports that companies above $10 million of annual revenue often see a 1.5x to 2x jump in valuation multiples as buyers price in infrastructure maturity and margin consistency. FOCUS does not say whether it means added turns or a multiplier on the multiple. The gap between those two readings is large, so treat the claim as directional and ask bidders for private comparables at your size. On $2 million of EBITDA at an assumed 6x ($12 million), added turns of 1.5 to 2 give $15 million to $16 million. A multiplier of 1.5 to 2 on the multiple gives 9x to 12x, or $18 million to $24 million (our arithmetic). Either way, each added turn on $2 million of EBITDA is worth $2 million of enterprise value.

Worked example: the platform arbitrage. Assume a platform buys a practice with $2 million of EBITDA at 6x and is itself valued at 10x (both assumed). The purchase costs $12 million. Inside the platform, the same EBITDA is worth $20 million. That $8 million gap (our arithmetic) is why platforms buy small practices and sell at scale. A solo owner can capture part of it by joining a group before selling, at a cost in governance, integration and time.

Worked example: owner pay normalization. Buyers rebuild EBITDA as if a hired physician did the owner's clinical work. Assume a practice reports $1.5 million of EBITDA after paying its owner $400,000, and a replacement physician costs $550,000 at market (illustrative inputs). Adjusted EBITDA falls to $1.35 million. At an assumed 7x, that $150,000 adjustment cuts enterprise value by $1.05 million (our arithmetic). The logic runs in reverse for an owner who overpays themself, and it applies to related-party rent above or below fair market value. For staff wage benchmarks, the BLS Health Care and Social Assistance page links current employment and wage data.

Quality of earnings item Buyer's adjustment Effect on the seller
Owner compensation Reset to market pay for the replacement clinician Lowers EBITDA if the owner is underpaid
Related-party rent Reset to fair market rent Lowers EBITDA if rent is below market
One-time costs Added back with documentation Raises EBITDA
Payer contracts near renewal Rate risk priced in Lowers value if a major contract is at risk
Provider concentration Revenue at risk if one clinician leaves A lower multiple or a larger earnout
Payer mix Government share tested against rate trends Medicare was 21% of US health spending in 2024, per CMS, so rate changes there reach most practices

Before you go to market, write a one-page answer covering payer mix, rate trend by service line and who runs daily operations if the founder cuts back. If you can't name that operator, expect a lower multiple, a larger earnout or a longer employment term. Our practice valuation calculator applies multiple ranges to your EBITDA.

From Headline Price to Cash at Closing: A $45 Million Worked Example

Assumptions (illustrative, not market data). - A regional specialty platform with $5 million of EBITDA sells at an assumed 9x, for a headline enterprise value of $45 million. - The LOI sets consideration at 75% cash, 15% rollover equity and 10% earnout, each as a share of headline enterprise value. - The deal is cash-free and debt-free. The buyer prices the business as if it had no cash and no debt. The seller holds no cash in this example and repays its own $3.0 million of bank debt out of the purchase price at closing. That payoff comes out of the seller's closing cash, which makes equity value $42 million. - The indemnification escrow is sized on headline enterprise value: 10% without representations and warranties insurance (RWI), and an assumed 1% with it. With RWI, the seller's escrow is negotiated against the policy retention, so treat 1% as a starting assumption until you hold a quote.

Line Arithmetic No RWI With RWI
Headline enterprise value $5.0M × 9 $45.00M $45.00M
Rollover equity (illiquid, at issue value) $45M × 15% $6.75M $6.75M
Earnout (contingent, undiscounted) $45M × 10% $4.50M $4.50M
Cash consideration $45M × 75% $33.75M $33.75M
Less indemnification escrow 10% or 1% of $45M ($4.50M) ($0.45M)
Less debt payoff Assumed input ($3.00M) ($3.00M)
Net cash at closing, before fees and taxes $26.25M $30.30M
Net cash as a share of headline 58% 67%
Adviser and legal fees, RWI premium if any Use your own figures

These are shares of headline value before adviser fees, legal costs and taxes, not take-home proceeds. Without RWI, an owner who hears "$45 million" receives $26.25 million at closing. The $4.5 million escrow comes back on its release date, less any claims. The rollover is worth $6.75 million only if the platform's next sale goes well. If a bidder offers RWI, ask who pays the premium and the retention before you compare.

What the earnout is worth. Value it at your odds of collecting, not at face value.

Probability of hitting the earnout Expected earnout value Expected total (no RWI, escrow fully released, rollover at issue value)
25% $1.125M $38.625M
50% $2.25M $39.75M
75% $3.375M $40.875M

Each expected total is net closing cash ($26.25M) plus released escrow ($4.5M), rollover ($6.75M) and the expected earnout (our arithmetic). Totals are undiscounted and before fees and taxes. A dollar paid two years out is worth less than a dollar today, so the earnout value calculator also applies a discount rate.

Worked example: the lower offer that pays more at closing. Offer B is $42 million with 90% cash, 10% rollover and no earnout, with the same 10% escrow rate and $3.0 million payoff.

Offer A Offer B
Headline enterprise value $45.00M $42.00M
Cash consideration $33.75M $37.80M
Escrow at 10% of headline ($4.50M) ($4.20M)
Debt payoff ($3.00M) ($3.00M)
Net cash at closing, before fees and taxes $26.25M (58% of $45M) $30.60M (73% of $42M)
Rollover at issue value $6.75M $4.20M
Earnout at face $4.50M None
Expected total, escrow fully released $37.50M plus the expected earnout $39.00M

Offer B puts $4.35 million more in the seller's hands at closing on a $3 million lower headline (our arithmetic). Offer A wins on expected total only if the earnout has better than a 33% chance of paying ($1.5 million gap ÷ $4.5 million earnout), and only if you value its larger rollover at issue price. Both figures are undiscounted. Discounting the earnout and rollover for time and illiquidity raises that bar, so the two offers are less comparable than the totals suggest. When a buyer rejects your price, it is often rejecting the mix. Ask which term drove the refusal, then counter on the term you care about most, which for most sellers is closing cash. Run each version through the deal proceeds calculator.

Rollover diligence. Buyers pitch rollover as upside, so ask for their record: how many sellers held rollover, what each received at exit after dilution, and how rollover holders did in the sponsor's weaker deals. Then check your own terms for liquidation preferences, drag-along rights and what happens to your units if you leave. Our physician rollover equity checklist walks through each.

Pre-Market Readiness: Eight Workstreams That Protect Price and Closing Cash

Most value lost in a healthcare sale is lost in diligence, after exclusivity, when the seller has no competing bid to fall back on.

Workstream What "ready" looks like Who usually leads What it protects, in this page's examples
1. Normalized EBITDA Seller-side quality of earnings, every add-back documented, owner pay and rent reset to market Outside accountant A $150,000 owner pay adjustment cut value by $1.05 million at 7x
2. Payer and reimbursement file Payer mix by revenue, three years of rates by payer, a renewal calendar CFO or practice administrator Contracts near renewal are priced as risk to the multiple
3. Provider bench Compensation model, retention history, a named operator who runs daily work Founder and COO Provider concentration means a lower multiple or larger earnout
4. Compliance file Billing audit results, licensure records, a list of every financial relationship with physicians Compliance lead Items found after the LOI reopen price with a single buyer
5. Data room Indexed documents matching every claim in the CIM Banker Diligence answered from documents, not memory
6. Proceeds model A waterfall for each bid: cash, escrow, debt payoff, rollover, earnout Banker and seller Offer B paid $4.35 million more at closing on a lower headline
7. Debt and payoff Current payoff letters, equipment leases, other obligations settled at closing CFO The $3.0 million payoff came straight out of closing cash
8. Escrow and RWI An RWI quote in hand before bids arrive Banker with an insurance broker Escrow of $4.5 million without RWI vs an assumed $0.45 million with it

Order of work. Start with workstreams 1 and 2, since every bid is built on them. Run 3 and 4 alongside, because a founder dependency or an open compliance item takes longest to fix. Build the data room and proceeds model once the numbers are final, and refresh payoff letters just before closing.

Readiness test. If you can hand a buyer a normalized EBITDA bridge, a payer renewal calendar and the name of your operator in the first meeting, you are ready. If any one is missing, fix it before the teaser goes out.

LOI Terms to Lock Down Before You Grant Exclusivity

Every term left open in the LOI is negotiated later with one buyer and no competing bid. Use this table to decide what to settle while you still have leverage. Dollar figures come from the $45 million example above.

LOI term What to ask for What it is worth in this page's example
Cash share of headline Cash, rollover and earnout stated as separate dollar amounts Offer B's 90% cash paid $4.35 million more at closing than Offer A's 75%
Escrow size and release A stated percentage, a release date and a claims process $4.5 million held at 10% without RWI vs an assumed $0.45 million with it
RWI Who pays the premium and the retention, agreed in the LOI The gap between 58% and 67% of headline as closing cash
Debt and working capital A defined payoff amount and a working capital target based on your normal months The $3.0 million payoff came straight out of closing cash
Earnout metric A metric you control, a clear measurement method and payment if the buyer resells the business $4.5 million at face, worth $1.125 million at 25% odds
Rollover rights Same class of units as the sponsor, tag-along rights and fair terms if you leave $6.75 million at issue value, realized only at the platform's next sale
Banker fee timing Fee on rollover and earnout paid when that value is received $225,000 of fees otherwise due on value not yet received in cash
Employment term Length, pay and what happens to rollover and earnout if you leave early A shorter term with little rollover suits an owner near retirement
Closing conditions and timeline Any regulatory filings and third-party consents listed, with a target closing date A missed filing pushes back the date your closing cash arrives
Exclusivity window A short period with milestones the buyer must hit to extend it Your leverage ends the day exclusivity starts
Deal structure Asset or stock sale settled, with after-tax proceeds modeled for each Tax can move net proceeds by more than the gap between two bids

Regulatory reviews, rules on who may own a medical practice and rules on financial relationships with referring physicians can all affect closing timing and deal structure. Raise each one with your own attorney before the LOI. Our guides to the healthcare M&A process, healthcare compliance due diligence, management services organizations, HSR and state transaction notices and Stark, anti-kickback and corporate practice of medicine give the background. Model asset versus stock structure with your tax adviser using the same proceeds waterfall you built for each bid.

Raising Capital From Physicians and Family Offices

PE deal counts measure fund-led buyouts, add-ons and growth rounds. A founder raising a minority round from individuals and family offices runs a different process: a private placement, closed one investor at a time. To see which healthcare companies have raised private capital and how much, search private offering notices filed with the SEC in SEC EDGAR full-text search. Our guide to capital raising for healthcare companies covers the process.

Capital source What they want What they offer Watch for
PE growth equity (214 growth investments in PESP's 2025 count) A minority stake, protective rights and an exit within a set window Large checks and operating help Redemption rights and exit timing
Single and multi-family offices A long hold, direct access and co-investment rights Patient capital and flexible structure Slower decisions and uneven healthcare expertise
Physician investors Clinical upside in a business they understand Credibility and clinical insight Overlap between their investment and their referrals (see the physician investor guide)
Senior or unitranche debt Covenants and cash interest Capital without dilution Covenant headroom when reimbursement shifts
SBA 7(a) loan Personal guarantees and a lender's credit review A program loan limit that can change. Confirm the current limit with your lender or the SBA The program limit may rule it out for larger platforms

Family offices and generalist investors often lack a framework for judging a healthcare deal. Build the diligence package before the first meeting:

Round design choice Option that closes faster Why
First close size What investors you already know can fund A first close builds credibility for the rest of the round
Security Simple preferred or common units with a clear preference Family offices spend less time on bespoke terms
Information rights Quarterly financials and an annual payer mix report Answers the reimbursement question before investors ask
Use of proceeds One or two named milestones Ties the valuation to something investors can verify

Our guide to raising capital from physician investors covers targeting and structure, and the healthcare data room checklist gives a starting list.

For Readers Considering a Career in Healthcare Investment Banking

Healthcare groups at large banks usually split by subsector: providers and services, health IT, medtech and products, and biopharma. Large-bank groups lean toward health systems, listed companies and biopharma. Middle-market and boutique firms run more sell-side processes for practices and platforms, often in narrow teams around physician practices, dental, behavioral health or post-acute care.

Role Core work in a provider services group
Analyst EBITDA bridges from practice financials, comparable deal sets, buyer lists
Associate Confidential information memoranda, data rooms, diligence management
Vice president Runs the process day to day and manages buyers and the deal team
Managing director Originates mandates and holds platform and sponsor relationships
Skill that sets candidates apart How to build it
Normalizing practice EBITDA Rebuild a sample practice P&L at market owner pay and fair market rent
Proceeds waterfalls Rebuild Offer A and Offer B above from the assumptions alone, then change escrow and debt
Reimbursement literacy Learn how commercial, Medicare and Medicaid rates differ by service line
Buyer mapping List the platforms active in one specialty and region
Sector multiples Explain why a listed multiple is not a private bid

The deal data shows where the work is. Add-ons, dental, outpatient specialties and health IT produced most of the PE deal flow PESP tracked in 2025. Hospital work centers on not-for-profit systems, mega mergers and divestitures. Exit paths follow the buyer universe. PESP counted 708 investment firms and 420 platform companies in 2025 PE healthcare deals, and those firms are where bankers move next, into healthcare private equity, growth equity or platform corporate development. Not-for-profit systems, the most common hospital acquirers in Kaufman Hall's Q3 2026 data, hire for strategy and M&A roles too. Clinical or operating experience helps in every one of these seats, because diligence in this sector turns on reimbursement and physician economics.

Questions Practice Owners and Investors Ask

What EBITDA multiple will my healthcare company sell for in 2026?

Your sector and your size set the range. Damodaran's January 2026 data for listed US companies puts Healthcare Information and Technology at 21.27x EV/EBITDA, Healthcare Products at 19.78x, Healthcare Support Services at 11.17x and Hospitals/Healthcare Facilities at 8.86x. These figures rank sectors. They are not bids for a private practice. FOCUS Investment Banking's 2026 dashboard reports that companies above $10 million of annual revenue often see a 1.5x to 2x jump in valuation multiples. On $2 million of EBITDA, each added turn is worth $2 million of enterprise value. Your final number depends on how much of your EBITDA survives the buyer's quality of earnings review.

How should I compare offers that include an earnout or rollover equity?

Compare cash at closing first, then add contingent value at your own odds of collecting it. In our illustrative $45 million example, a 75% cash offer leaves $26.25 million at closing, or 58% of headline before fees and taxes, assuming a 10% escrow on headline and $3 million of debt payoff. A $42 million offer at 90% cash leaves $30.6 million on the same assumptions, $4.35 million more at closing. The higher offer wins on expected total only if its earnout has better than a 33% chance of paying and you value its rollover at issue price. Both figures are undiscounted, and discounting for time and illiquidity raises that bar.

Does selling a practice need federal or state regulatory clearance?

It can. Federal and state transaction reviews may come into play depending on deal size, location and structure. Whether a filing applies depends on the jurisdiction, the transaction details and the rules in force when you sign. A filing and its waiting period can set your earliest closing date. State rules on who may own a medical practice and rules on financial relationships with referring physicians can also shape the deal structure. Have your attorney map all of this before you sign a letter of intent, and build the timeline into the LOI. Our healthcare M&A process guide lists the questions to bring, and our HSR and state notice guide and state notice clocks chart cover the filings and their timing.

Sources